Summary

Eligibility
for people ages 18-70 (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
study ends around

Description

Summary

This is a Phase 1, open-label, single-arm, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of YN003 Injection in patients with recurrent or progressive glioma. The study consists of Part A (dose escalation using a Bayesian Optimal Interval design) and Part B (dose expansion at the recommended Phase 2 dose).

Official Title

A Phase 1, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of YN003 Injection in Patients With Glioma

Details

YN003 is an investigationalliposome injection designed to deliver the active drug preferentially to specific glioma tissue. Part A will evaluate ascending doses of YN003 administered by intravenous infusion once every 4 weeks to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D). The dose-limiting toxicity (DLT) observation period is 28 days. Approximately 21 to 30 DLT-evaluable subjects will be enrolled in Part A. Part B will enroll approximately 10 to 20 additional subjects at the RP2D to further evaluate safety, pharmacokinetics, and preliminary efficacy. The study will be conducted in the United States and China.

Keywords

Glioma, Glioblastoma, Brain Neoplasms, YN003, BOIN, recurrent, progressive, liposomal injection, Recurrence, YN003 Injection, Study Drug: YN003 Injection

Eligibility

You can join if…

Open to people ages 18-70

  • Voluntarily sign the informed consent form, understand the study, and be willing to comply with the protocol and complete all study procedures.
  • Male or female subjects 18 years ≤ aged ≤ 70 years.
  • Histologically confirmed recurrent or progressive glioma, including glioblastoma, as defined by the 2021 WHO Classification of Tumors of the Central Nervous System, Grade 3 to Grade 4, following standard therapy.Excluding re-irradiation for same lesions
  • Karnofsky Performance Status (KPS) ≥60.
  • At least one measurable lesion per RANO 2.0 criteria.
  • Have adequate hematologic, cardiac, hepatic, renal, coagulation, and pulmonary function at final screening.
  • Have completed the required washout period for prior therapies before dosing on Day
  • Corticosteroid dose must be stable or tapering within 7 days prior to dosing.

You CAN'T join if...

  • Participation in another interventional clinical study within 1 month prior to the date when subject signed the consent form.
  • Receipt of a live vaccine within 30 days prior to study treatment.
  • Pregnant or breastfeeding women.
  • Clinically significant intracranial hypertension (e.g., impending brain herniation or requiring urgent palliative intervention) or uncontrolled seizures. Subjects requiring antiepileptic drugs are eligible only if the dose has been stable for ≥ 14 days prior to first dosing
  • Toxicities from prior anticancer therapy that have not recovered to CTCAE v6.0 Grade ≤1, except for alopecia or other events considered tolerable by the investigator.
  • Contraindications to MRI, including but not limited to pacemakers, epicardial pacing leads, infusion pumps, aneurysm clips, metal fragments, metallic prostheses, magnetic implants, intraocular metal objects, or non-removable metallic dental implants.
  • Uncontrolled or severe cardiovascular or cerebrovascular disease

Locations

  • University of California, Los Angeles (UCLA) not yet accepting patients
    Los Angeles California 90095 United States
  • University of California, San Francisco (UCSF) not yet accepting patients
    San Francisco California 94158 United States
  • Beijing Tsinghua Changgung Hospital accepting new patients
    Beijing Beijing Municipality 102218 China
  • Sanbo Brain Hospital, Capital Medical University accepting new patients
    Beijing Beijing Municipality China

Details

Status
accepting new patients at some sites,
but this study is not currently recruiting here
Start Date
Completion Date
(estimated)
Sponsor
Beijing Inno Medicine Co., Ltd.
ID
NCT07929909
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 50 study participants
Last Updated